Cargando…
Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327531/ https://www.ncbi.nlm.nih.gov/pubmed/32350522 http://dx.doi.org/10.1093/eurheartj/ehaa344 |
| _version_ | 1783552562503352320 |
|---|---|
| author | Packer, Milton |
| author_facet | Packer, Milton |
| author_sort | Packer, Milton |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7327531 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73275312020-07-15 Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care Packer, Milton Eur Heart J Fast Track Clinical Research Oxford University Press 2020-04-29 /pmc/articles/PMC7327531/ /pubmed/32350522 http://dx.doi.org/10.1093/eurheartj/ehaa344 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Fast Track Clinical Research Packer, Milton Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care |
| title | Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care |
| title_full | Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care |
| title_fullStr | Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care |
| title_full_unstemmed | Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care |
| title_short | Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care |
| title_sort | are the benefits of sglt2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? expectations and realities of a new standard of care |
| topic | Fast Track Clinical Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327531/ https://www.ncbi.nlm.nih.gov/pubmed/32350522 http://dx.doi.org/10.1093/eurheartj/ehaa344 |
| work_keys_str_mv | AT packermilton arethebenefitsofsglt2inhibitorsinheartfailureandareducedejectionfractioninfluencedbybackgroundtherapyexpectationsandrealitiesofanewstandardofcare |